Business
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases.
Barinthus had no FY2025 revenue after a prior-year license row, while net loss, FCF burn, and equity erosion all worsened.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage immunotherapyNote
- Revenue — $0 vs $15.0MWatch
- Net income — -$66.4MWatch
- FCF — -$48.0MWatch
- Equity — $74.2M, -42.9%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman distress; Beneish and EQ unavailableWatch
Where the revenue comes from
Fiscal 2024, as Barinthus Biotherapeutics plc. reports it. History and quarterly detail are in the app.
- License revenue$15.0M
Leadership changes
From Barinthus Biotherapeutics plc.'s own filings, the day they're filed.
- Douglas Swirsky · Chief Financial Officer · appointmenteff. 2026-05-01
- Gemma Jones · Directors · departureeff. 2026-04-30
- Margaret Marshall · Chief Medical Officer · departure
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Barinthus Biotherapeutics plc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.